Literature DB >> 1650325

Prognosis of unresectable hepatocellular carcinoma: an evaluation based on multivariate analysis of 90 cases.

Y Akashi1, C Koreeda, S Enomoto, S Uchiyama, T Mizuno, Y Shiozaki, Y Sameshima, K Inoue.   

Abstract

A multivariate analysis of data from 90 patients with unresectable hepatocellular carcinoma was performed using Cox's regression model to identify factors possibly affecting their prognoses. Thirty-one patients underwent arterial anticancer chemotherapy, and the remaining 59 patients received transcatheter arterial embolization with anticancer agents. Four of 27 variables tested for all the patients (i.e., encapsulation [p less than 0.05], gross appearance of hepatocellular carcinoma [p less than 0.01], clinical stage [p less than 0.01] and therapy [p less than 0.01]) were found to be prognostically significant. Five of 27 variables tested were prognostically significant for the transcatheter arterial embolization group; they were an extension rate of hepatocellular carcinoma (p less than 0.01), encapsulation (p less than 0.01), alpha-fetoprotein (p less than 0.01), prothrombin time (p less than 0.01) and serum sodium (p less than 0.01). Regression equations were used to describe a prognostic index. A prognostic index was defined as the regression equation derived from the results of a total of 90 patients; PI-1 = eY, where PI-1 = prognostic index 1 Y = 1.549 (gross appearance of hepatocellular carcinoma - 1.344) + 0.778 (encapsulation - 1.622) + 0.818 (clinical stage - 1.800) + 1.760 (therapy - 1.344) and prognostic index 2, the regression equation derived from the results of the transcatheter arterial embolization group of patients; PI-2 = eY, where PI-2 = prognostic index 2 Y = 1.210 (extension rate of hepatocellular carcinoma - 1.576) + 1.179 (encapsulation - 1.475) + 0.0001277 (alpha-fetoprotein - 1420.792) -0.039 (prothrombin time - 72.237) - 0.214 (serum sodium - 138.427).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1650325

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  17 in total

1.  Gender-based outcomes differences in unresectable hepatocellular carcinoma.

Authors:  Shama C Buch; Venkateswarlu Kondragunta; Robert A Branch; Brian I Carr
Journal:  Hepatol Int       Date:  2007-12-15       Impact factor: 6.047

2.  Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis.

Authors:  P E Majno; R Adam; H Bismuth; D Castaing; A Ariche; J Krissat; H Perrin; D Azoulay
Journal:  Ann Surg       Date:  1997-12       Impact factor: 12.969

3.  Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation.

Authors:  Mike-S-L Liem; Ronnie-T-P Poon; Chung-Mau Lo; Wai-Kuen Tso; Sheung-Tat Fan
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

4.  Hepatocellular carcinoma in Central Europe: prognostic features and survival.

Authors:  M Schöniger-Hekele; C Müller; M Kutilek; C Oesterreicher; P Ferenci; A Gangl
Journal:  Gut       Date:  2001-01       Impact factor: 23.059

5.  Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome?

Authors:  Binkui Li; Yunfei Yuan; Guihua Chen; Liru He; Yaqi Zhang; Jinqing Li; Guohui Li; Wan Yee Lau
Journal:  BMC Cancer       Date:  2010-10-07       Impact factor: 4.430

6.  [Palliative therapy of primary liver tumors].

Authors:  C Kelm; K Henneking; T Zimmermann; M Vollerthun; W Padberg
Journal:  Langenbecks Arch Chir       Date:  1993

7.  Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival.

Authors:  Tammy T Chang; Rajiv Sawhney; Alexander Monto; J Ben Davoren; Jacob G Kirkland; Lygia Stewart; Carlos U Corvera
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

8.  Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC.

Authors:  Hye Jin Choi; Byung Chul Cho; Joo Hyuk Sohn; Sang Jun Shin; Se Hyun Kim; Joo Hang Kim; Nae Choon Yoo
Journal:  J Neurooncol       Date:  2008-10-23       Impact factor: 4.130

9.  Adjuvant intraportal venous chemotherapy for patients with hepatocellular carcinoma and portal vein tumor thrombi following hepatectomy plus portal thrombectomy.

Authors:  Li-Jian Liang; Wen-Jie Hu; Xiao-Yu Yin; Qi Zhou; Bao-Gang Peng; Dong-Ming Li; Ming-De Lu
Journal:  World J Surg       Date:  2008-04       Impact factor: 3.352

Review 10.  Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies.

Authors:  Puneeta Tandon; Guadalupe Garcia-Tsao
Journal:  Liver Int       Date:  2008-12-24       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.